SS-31 vs MOTS-c: What the Research Shows
SS-31 and MOTS-c side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider SS-31 if…
- you want a product with an FDA label: Forzinity (elamipretide) is indicated, under accelerated approval, to improve muscle strength in Barth syndrome[23]
- you want the randomized trial record (mitochondrial myopathy): the pivotal trial missed its primary endpoints: The pivotal randomized trial did not meet its primary endpoints (6-minute walk and fatigue score).[5]
- you are tested in sport and want to avoid a WADA-prohibited substance: MOTS-c is prohibited by WADA at all times (check SS-31 (elamipretide)'s own status separately)[3]
Consider MOTS-c if…
- you are weighing human evidence that, in our search, only measured the body's own MOTS-c (none gave it as a treatment): exercise raised plasma MOTS-c in non-Hispanic White survivors but not Hispanic survivors[16]
Spec comparison
Showing 11 of 13 fields where the two differ. Half-life, Evidence strength are the same or both unknown.
| Field | SS-31 | MOTS-c |
|---|---|---|
| Class | Mitochondria-targeting peptide | Mitochondrial-derived peptide |
| Also called | elamipretide, Forzinity | mots |
| Category | Longevity | GLP-1 & metabolic |
| FDA status | FDA accelerated approval for Barth syndrome (Sep 2025) | PCAC voted 7–5 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized |
| WADA | Not on the WADA Prohibited ListSS-31 (elamipretide) is not named on the list. It received FDA accelerated approval in 2025, so the S0 catch-all does not apply to it. | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Ophthalmology science 2025, PMID 39605874 | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 |
| Human studies we summarised | 12 human (8 randomized or controlled) of 15 summarised | 7 human (4 randomized or controlled) of 15 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 10 mg, 25 mg, 50 mg | 5 mg, 10 mg, 20 mg, 40 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
SS-31 and MOTS-c together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
A drug with phase 2 and 3 trials versus a biomarker peptide
A randomised SS-31 (elamipretide) trial in mitochondrial disease did not meet its primary endpoints assessing changes in the 6MWT and PMMSA total fatigue score.[5]
In that trial the difference from placebo in distance walked on the 6MWT from baseline to week 24 was -3.2 meters (95% CI -18.7 to 12.3; p = 0.69).[5]
In an elamipretide trial in dry macular degeneration, the primary endpoints (mean change in LL BCVA and in the square-root-converted GA area) did not reach statistical significance.[4]
In Barth syndrome, neither primary endpoint was met in part 1 of the SS-31 study.[6]
MOTS-c's efficacy data here are in mice: a 5% muscle loss with MOTS-c against about 15% with immobilization.[27]
Approval, dosing and sport
Forzinity (elamipretide) is labelled to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.[23]
The label's recommended dosage for patients weighing at least 30 kg is 40 mg subcutaneously once daily.[23]
Injection-site reactions are the commonest adverse reactions listed on the label.[23]
The Drugs@FDA lookup for MOTS-c came back with 'No matches found!'.[28]
Common questions
Is SS-31 better than MOTS-c?
The cached mitochondrial-disease trial of SS-31 did not meet its primary endpoints. MOTS-c's efficacy data here are in mice.[5]
Is SS-31 FDA approved?
Yes, as elamipretide (Forzinity) for Barth syndrome in people weighing at least 30 kg.[23]
Can you stack SS-31 and MOTS-c?
A PubMed search on 2 Oct 2026 for MOTS-c with elamipretide or SS-31 matched 1 record; it is not recorded as a study of the pair.
Calculated from records matched 1; search date 2026-10-02; query note MOTS-c AND (elamipretide OR Bendavia OR MTP-131 OR Forzinity OR SS-31 with peptide/mitochondria terms). Formula: records_matched = PubMed count recorded in combinations.json (mots-c__ss-31) for the query on search_date
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.Ophthalmology science · 2025PMID 39605874Accessed 2 Oct 2026
- 5Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.Neurology · 2023PMID 37268435Accessed 2 Oct 2026
- 6A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.Genetics in medicine : official journal of the American College of Medical Genetics · 2021PMID 33077895Accessed 2 Oct 2026
- 7PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) (526 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (randomized[tiab] OR trial[tiab] OR patients[tiab]) (133 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: elamipretide[tiab] AND (TAZPOWER[tiab] OR "Barth syndrome"[tiab]) AND (randomized[tiab] OR crossover[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: elamipretide[tiab] AND (macular[tiab] OR "geographic atrophy"[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: elamipretide[tiab] AND (fibromyalgia[tiab] OR fatigue[tiab] OR "chronic pain"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 14Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 15Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 16Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 17PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab])))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23FORZINITY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 24Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 25PubMed search: (elamipretide[tiab] OR Bendavia[tiab] OR "MTP-131"[tiab] OR Forzinity[tiab] OR (("SS-31"[tiab] OR SS31[tiab]) AND (peptide*[tiab] OR mitochondri*[tiab] OR cardiolipin[tiab] OR Szeto[tiab]))) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (77 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 26PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 27Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.American journal of physiology. Endocrinology and metabolism · 2024PMID 38170165Accessed 2 Oct 2026
- 28Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.